

Product Data Sheet

Product Name: NN1177 (trifluoroacetate salt)

Cat. No.: GC92131

Chemical Properties

Cas. No.

SMILES NC([C@@]([C@H](O)C)([H])NC([C@H](CCCCNC(CC[C@@H](C(O)=O)NC(CC[C@@H](C(O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC(CC[C@H](NC(CC[C@H](NC(CCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)C(O)=O)=O)CO)=O)CCC(O)=O)=O)CO)=O)=O)=O)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@@H](NC([C@H](CCC(N)=O)NC([C@H](C(C)C)NC([C@@H](NC([C@H](CCC(O)=O)NC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@H](CCCCN)NC([C@H](CO)NC([C@H](CCC(O)=O)NC([C@H](CC(C)C)NC([C@@H](NC([C@H](CCCCN)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@@H](NC([C@H](CO)NC([C@@]([C@H](O)C)([H])NC([C@@H](NC([C@@]([C@H](O)C)([H])NC(CNC([C@H](CCC(N)=O)NC(C(C)(C)NC([C@@H](N)CC1=CN=CN1)=O)=O)=O)=O)=O)CC2=CC=CC=C2)=O)=O)=O)CC(O)=O)=O)=O)=O)CC(C=C3)=CC=C3O)=O)=O)=O)=O)=O)C)=O)=O)=O)CC4=CC=CC=C4)=O)=O)=O)CC5=CNC6=C5C=CC=C6)=O)=O)=O)=O)=O.FC(F)(F)C(O)=O


Formula C₂₀₆H₃₂₃N₅₁O₆₆ ? XCF₃COOH M.Wt 4570.1

Solubility Acetonitrile: Slightly soluble: 0.1-1 mg/ml, DMSO: Sparingly soluble: 1-10 mg/ml, Water: Slightly soluble: 0.1-1 mg/ml Storage -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

NN1177 is a dual peptide agonist of the glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R).¹ It induces cAMP production in BHK-21 cells expressing human GCGR or GLP-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

1R (EC₅₀s = 1.83 and 0.92 pM, respectively). *In vivo*, NN1177 (3-5 nmol/kg) reduces body weight and cumulative food intake in a mouse model of diet-induced obesity. It also reduces body weight, hepatic fat accumulation and fibrosis, and plasma alanine transaminase (ALT) levels in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a high-fat, high-fructose, and high-cholesterol diet.²

References:

- [1]. Simonsen, L., Lau, J., Kruse, T., et al. Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls PLoS One 17(3)e0264974(2022).
- [2]. Monfeuga, T., Norlin, J., Bugge, A., et al. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients Mol. Metab. 79101850(2024).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA